Abstract
Background: Thrombomodulin (TM) is an endothelial cell surface thrombin‐binding protein with anticoagulation ability by thrombin‐mediated activation of protein C. An increase of plasma soluble TM level is reported to be associated with severity and worse outcome of coronary artery disease.
Hypothesis: This prospective study investigated the relation of the elevated levels of plasma soluble TM and inflammatory and myonecrotic markers in patients undergoing percutaneous coronary intervention (PCI).
Methods: Plasma levels of soluble TM, C‐reactive protein (CRP), and creatine kinase and its MB isoenzyme were measured before and after PCI in 100 patients undergoing PCIs.
Results: Peak TM levels after PCIs were significantly higher thanbaseline (3.39 ± 1.63 vs. 2.90 ± 1.57 ng/ml, p< 0.001). The peak TM levels after PCIs correlated significantly with the peak CRP and MB levels, and the maximal inflation duration (r = 0.423, p<0.001; r = 0.212, p = 0.034; r = 0.307, p = 0.002, respectively).
Conclusions: Soluble TM levels increase significantly after PCI. The elevation of the soluble TM after PCI shows better correlation with inflammation than myocardial injury, indicating an endothelial origin. Measurement of soluble TM could be useful and calls for further studies on the prognostic effects of this marker in this clinical condition.
Keywords: thrombomodulin, inflammation, percutaneous coronary intervention
Full Text
The Full Text of this article is available as a PDF (36.2 KB).
References
- 1. Esmon CT: Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J 1995; 9: 946–955 [DOI] [PubMed] [Google Scholar]
- 2. Ishii H, Uchiyama H, Kazama M: Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 1991; 65: 618–623 [PubMed] [Google Scholar]
- 3. Fager G: Thrombomodulin and proliferation of vascular smooth muscle cells. Circ Res 1995; 77: 645–650 [DOI] [PubMed] [Google Scholar]
- 4. Blann AD, Seigneur M, Steiner M, Boisseau MR, McCollum CN: Circulating endothelial cell markers in peripheral vascular disease: Relationship to the location and extent of atherosclerotic disease. Eur J Clin Invest 1997; 27: 916–921 [DOI] [PubMed] [Google Scholar]
- 5. Blann AD, Amiral J, McCollum CN: Circulating endothelial cell/leukocyte adhesion molecules in ischemic heart disease. Br J Haematol 1996; 95: 263–265 [DOI] [PubMed] [Google Scholar]
- 6. Li YH, Chen JH, Wu HL, Shi GY, Huang HC, Chao TH, Tsai WC, Tsai LM, Guo HR, Wu WS, Chen ZC: G‐33 A mutation in the promotor region of thrombomodulin gene and its association with coronary artery disease and plasma soluble thrombomodulin levels. Am J Cardiol 2000; 85: 8–12 [DOI] [PubMed] [Google Scholar]
- 7. Ishiwata S, Tukada T, Nakanishi S, Nishiyama S, Seki A: Postangioplasty restenosis: Platelet activation and the coagulation‐fibrinolysis system as possible factors in the pathogenesis of restenosis. Am Heart J 1997; 133: 387–392 [DOI] [PubMed] [Google Scholar]
- 8. Ross R, Glomset JA: Atherosclerosis and the arterial smooth muscle cell. Science 1973; 180: 1332–1339 [DOI] [PubMed] [Google Scholar]
- 9. Blann AD, Amiral J, McCollum CN: Prognostic value of increased soluble thrombomodulin and increased soluble E‐selectin in ischemic heart disease. Eur J Haematol 1997; 59: 115–120 [DOI] [PubMed] [Google Scholar]
- 10. Salomaa V, Matei C, Aleksic N, Sansores‐Garcia L, Folsom AR, Juneja H, Chambless LE, Wu KK: Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: A case‐cohort study. Lancet 1999; 353: 1729–1734 [DOI] [PubMed] [Google Scholar]
- 11. Oh JK, Shub C, Ilstrup DM, Reeder GS: Creatine kinase release after successful percutaneous trans luminal coronary angioplasty. Am Heart J 1985; 109: 1225–1231 [DOI] [PubMed] [Google Scholar]
- 12. Karim MA, Shinn MS, Oskarsson H, Windle J, Deligonul U: Significance of cardiac troponin T release after percutaneous transluminal coronary angioplasty. Am J Cardiol 1995; 76: 521–523 [DOI] [PubMed] [Google Scholar]
- 13. Azar RR, McKay RG, Kiernan FJ, Seecharran B, Feng YJ, Fram DB, Wu AH, Waters DD: Coronary angioplasty induces a systemic inflammatory response. Am J Cardiol 1997; 80; 1476–1478 [DOI] [PubMed] [Google Scholar]
- 14. Salvioni A, Galli S, Marenzi G, Lauri G, Perego GB, Assanelli E, Guazzi MD: Thrombin activation and late restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1998; 135: 503–509 [DOI] [PubMed] [Google Scholar]
- 15. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ: Atherosclerosis: Basic mechanisms—oxidation, inflammation, and genetics. Circulation 1995; 91: 2488–2496 [DOI] [PubMed] [Google Scholar]
- 16. Kloner RA, Giacomelli F, Alker KJ, Hale SL, Matthews R, Bellows S: Influx of neutrophils into the walls of large epicardial coronary arteries in response to ischemia/reperfusion. Circulation 1991; 84: 1758–1772 [DOI] [PubMed] [Google Scholar]
- 17. Conway EM, Van de Wouwer M, Pollefeyt S, Jurk K, Van Aken H, De Vriese A, Weitz JI, Weiler H, Hellings PW, Schaeffer P, Herbert JM, Collen D, Theilmeier G: The lectin‐like domain of thrombomodulin confers protection from neutrophil‐mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappa B and mitogen‐activated protein kinase pathway. J Exp Med 2002; 196: 565–577 [DOI] [PMC free article] [PubMed] [Google Scholar]